Introduction
============

Osteoarthritis (OA), a disease of articular joints, is associated with significant morbidity, mortality, physical disability, and increased healthy care expenditures in middle age and elderly individuals ([@B13]; [@B15]). An improved understanding of disease pathogenesis and advances in the investigation of biomarkers is facilitating much emphasis in the prevention and treatment of early OA ([@B12]). Traditionally, a variety of treatment options for OA consists of pain management for early stage disease through medication. Pharmaceuticals, especially non-steroidal anti-inflammatory drugs (NSAIDs), already play an important part in symptom control ([@B16]). However, the long-term uses of these drugs may produce severe adverse effects. In addition, none has so far been approved by regulators, which require concurrent symptom amelioration and disease modification ([@B5]).

Traditional Chinese medicine (TCM) acts as the promising alternative medicine as a therapeutic option for OA ([@B19]). According to the TCM theory, the primary pathogenesis of OA is insufficiency of liver and kidney ([@B4]). Based on the therapeutic principle, a classic TCM formula Yougui pills (YGPs) which is first recorded in *Jingyue quanshu* has been used to treat Kidney-Yang Deficiency Syndrome with a history of about 400 years in China. Previous study published in Chinese language showed that YGPs has chondroprotective effects on OA ([@B23]). Although YGPs has been proved effective in OA treatment, the precise mechanism and drug action target is still poorly understood.

Cartilage degeneration is a remarkable feature of OA and it may be an important pathological event contributing to the development of OA. The characteristics of articular cartilage degradation include proteoglycans and collagen degeneration, chondrocyte clustering, fibrillation and osteophyte formation ([@B33]). However, adult mammal's articular cartilage appears to show a poor ability of repairing itself throughout life ([@B20]; [@B6]). The transforming growth factor beta (TGF-β) signaling in cartilage which is responsible for regulating the synthesis and degradation of extracellular matrix (ECM) protein, for controlling the proliferation and differentiation of chondrocyte and for inhibiting it hypertrophy and maturation plays a crucial role in pathogenesis of OA ([@B1]; [@B24]; [@B7]). Recently, related studies showed that inhibition of TGF-β signaling in cartilage induces articular cartilage degradation ([@B1]; [@B26]; [@B32]). Therefore, pharmacological activation of TGF-β signaling has been proposed to maintain articular cartilage integrity during OA ([@B1]).

The aim of the current study was the histological observation of the chondroprotective effect of YGPs on OA progression in the articular cartilage of wild type (WT) and *Tgfbr2* conditional knockout (cKO) mice. We hypothesized that the chondroprotective activity of YGPs on OA *in vivo* based on enhancing TGF-β/Smad signaling in articular cartilage.

Materials and Methods {#s1}
=====================

Reagents
--------

DNA extraction kit and Tamoxifen were purchased from Sigma--Aldrich (Sigma-Aldrich, St. Louis, MO, United States). 4% paraformaldehyde, 14% elhylene diamine tetraacetic acid (EDTA) and citrate buffer were purchased from Solarbio (Solarbio, Beijing, China). Normal goat serum, secondary biotinylated goat anti-mouse antibody and diaminobenzidine (DAB) solution were obtained from Invitrogen (Invitrogen, Frederick, MD, United States). COL-2, MMP-13 and pSMAD-2 primary antibodies were brought from Abcam (Abcam, Cambridge, MA, United States).

Preparation of YGPs
-------------------

Yougui pills were produced by Henan Wanxi Pharmaceutical Co. Ltd. (Batch number: Z41022170) Small amount of sample was deposited as voucher specimen in institute of orthopedics and traumatology, Zhejiang Chinese Medical University with voucher specimen No. GYS-2015-0016. YGPs comprise 10 kinds of herbal medicines (**Table [1](#T1){ref-type="table"}**). The production process was based on the standards of Chinese Health and Family Planning Commission. Briefly, *Cervicornuscolla* was firstly melted with wine by heat and the other nine herbal medicines were ground to fine powder. Every 100 g powder was mixed with 65 g molten *Cervicornuscolla* and honey ([@B18]). The high performance liquid chromatography (HPLC) detection was performed to analysis of and the quality control of YGPs. The analysis procedure was conducted according to the previous reports ([@B21]). Ten of the major constituents including betaine, sweroside, loganin, hyperin, quercitrin, chlorogenic acid, songorine, fuziline, neoline and cinnamaldehyde were determined in our study.

###### 

The compositions of Yougui pills (YGPs).

  Chinese name   Botanical name                          Latin name                           Weight (g)   Parts used
  -------------- --------------------------------------- ------------------------------------ ------------ ------------
  Shu di huang   *Rehmannia glutinosa* (Gaertn). DC.     *Rehmanniae radix praeparata*        240          Root
  Shao yao       *Dioscorea oppositifolia* L.            *Dioscoreaerhizoma*                  120          Rootstock
  Shan zhu yu    *Cornus officinalis* Sieb. EtZucc.      *Cornifructus*                       90           Fruit
  Gou qi zi      *Lyciumbarbarum* L.                     *Lyciifructus*                       120          Fruit
  Lu jiao jiao   *Cervus elaphus* Linnaeus               *Cervicornuscolla*                   120          Horn
  Tu si zi       *Cuscuta chinensis* Lam.                *Cuscutae semen*                     120          Fruit
  Du zhong       *Eucommia ulmoides* Oliv.               *Eucommiae cortex*                   120          Bark
  Dang gui       *Angelica sinensis* (Oliv.) Diels       *Angelicaesinensis radix*            90           Root
  Rou gui        *Cinnamomum cassia* (L.) J. PreslBark   *Cinnamomi cortex*                   60           Bark
  Fu zi          *Aconitum carmichaeli* Debx.            *Aconitilateralis radix preparata*   60           Root

Animals
-------

Male C57BL/6J mice (10 weeks old) were obtained from Shanghai Laboratory Animal Center of Chinese Academy of Sciences (Grade SPF II, SCXK 2012-0002). *Col2-CreER* and *TGF-βRII^fx/fx^* mice (background: C57BL/6J) were donated from Rush University Medical Center (Chicago, IL, United States). In order to specifically knock out *Tgfbr2* gene in articular cartilage, *TGF-βRII^fx/fx^* mice were cross with *Col2-CreER* mice to generate *Col2-CreER; TGF-βRII^fx/fx^* mice (*TGF-βRII^Col2ER^* mice) ([@B26]). Genotyping was performed by polymerase chain reaction (PCR) using a DNA extraction kit tail biopsy tissues (Supplementary Figure [S1](#SM1){ref-type="supplementary-material"}). PCR primer sequences as follows: primer sequences of *Cre*, upper primer 5′-ATTGCTGTCACTTGGTCGTGGC-3′ and lower primer 5′-GAAAATGCTTCTGTCCGTTTGC-3′ (200-base-pair PCR product); primer sequences of *Tgfbr2* loxP, upper primer 5′-TAAACAAGGTCCGGAGCCCA-3′ and lower primer 5′-ACTTCTGCAAGAGGTCCCCT-3′ (Wild-type, 420-base-pair PCR product; homozygotic type, 540-base-pair PCR product). *TGF-βRII^fx/fx^* littermates were used as controls ([@B31]; [@B27]; [@B3]). After identification of genotypes, *TGF-βRII^Col2ER^* mice were induced by tamoxifen (1 mg/10 g body weight/day, i.p.) for five successive days at age of 2-week-old ([@B26]). All mice were housed in a temperature (23 ± 2°C) and humidity (40 ± 5%) controlled room, exposed to a controlled 12 h cycle of light and darkness with a solid rodent chow and water *ad libitum*. All studies were approved by the Committee on the Ethics of Animal Experiments of Zhejiang Chinese Medical University.

Surgical Preparation
--------------------

Knee OA model was induced to C57 mice at age of 10-week-old by destabilization of the medial meniscus (DMM) as previous report ([@B17]). Briefly, DMM surgery was performed on the right hind limbs of WT mice as follows: (1) After a 3 mm longitudinal incision was made on the medial part of the knee under anesthesia, blunt dissection of the knee extensor muscles and patellar ligament was performed to expose the medial meniscotibial ligament (MMTL); (2) The MMTL was transected to give DMM; (3) The medial joint capsule was sutured, and the skin was closed. The sham surgery was also performed by a similar surgical approach without manipulating the joint tissue in WT mice.

Experimental Protocol
---------------------

All mice were randomly divided into six groups: the sham group, the model group, the model YGPs group, the *TGF-βRII^fx/fx^* group, the *TGF-βRII^Col2ER^* group and the *TGF-βRII^Col2ER^* + YGPs group (*n* = 10 in each group). YGPs were orally administered to both WT and *TGF-βRII^Col2ER^* mice once a day after DMM surgery and tamoxifen inducement respectively for 12 consecutive weeks with dose of 3.5 g/kg body weight. The dose administered was determined according to the following formula: *D*~M~ (dose per kg body weight) = *D*~H~ × *R* × (*W*~H~/*W*~M~), as detailed in The Methodology of Pharmacological Experiment. *D*~M~ and *D*~H~ are doses for mice and humans, and *W*~M~ and *W*~H~ are body weights of mice and humans, respectively. *R* is the coefficient of 0.0026 for human mouse equivalent dosage conversion ([@B34]). The mice in sham and *TGF-βRII^fx/fx^* group were given an equal dosage of physiologic saline. Knee joint samples from each group were harvested at the end of drug intervention period for the follow-up experiments.

Assessment of Articular Cartilage Degradation
---------------------------------------------

Knee joints of each group were successively fixed in 4% paraformaldehyde for 3 days and decalcified with 14% EDTA solution for 14 days. The samples were embedded in paraffin, and a series of histologic sections (3 μm) were stained with Alcian Blue Hematoxylin/Orange G and Toluidine Blue. The image of sections was collected under a light microscope (Axio Scope A1, ZEISS, Germany). Next, Histomorphometric analysis was performed using OsteoMeasure software (OsteoMetrics, Inc., Atlanta, GA, United States) to calculate and determine the area and thickness of cartilage. Moreover, according to Osteoarthritis Research Society International (OARSI) recommendations ([@B11]), cartilage degeneration was scored by two blinded observers. The summed score for the knee joint (determined by summing the scores for the femoral condyle and tibial plateau) was used to evaluate the extent of cartilage degradation.

Micro-CT Analysis
-----------------

The representative knee joint images of mice were obtained from micro-CT equipment (Skyscan 1176, Bruker microCT N.V., Kontich, Belgium). The pictures were taken with a resolution of 4000 × 2672 pixels and an isotropic voxel size of 9 μm. In addition to the visual assessment of structural pictures, quantitative morphometry indexes were determined from micro-tomographic data based on the 3-D morphometry ([@B14]). The region of interest was identified between the proximal tibia growth plate and tibial plateau. And the following indexes were evaluated subsequently: (1) bone volume fraction (BV/TV, %); (2) average trabecular thickness (Tb. Th, mm); (3) average trabecular separation (Tb. Sp, mm).

Immunohistochemistry
--------------------

We also performed immunohistochemistry to analyze the expressions of type II collagen (COL-2), matrix metalloproteinase 13 (MMP-13) and phosphorylated protein mothers against decapentaplegic homolog 2 (pSMAD-2) in articular cartilage. The paraffin sections were heated at 60°C overnight, then deparaffinized and rehydrated. Next, the sections were incubated with 3% hydrogen peroxide to block endogenous peroxidase activity for 20 min. the sections were incubated in 0.1 mol/L citrate buffer (Zhongshan jinqiao, Beijing, China) at 95°C with water bath for 20 min as antigen retrieval. Immunohistochemistry analysis was achieved using primary antibodies of COL-2 (diluted 1:1000), MMP-13 (diluted 1:100) and pSMAD-2 (diluted 1:100) at 4°C overnight. After washing, the sections were incubated with the HRP-conjugated secondary antibody at room temperature for 30 min. After incubated with DAB, counterstained with hematoxylin for 2 s, positive staining of sections was observed under a light microscope (Axio Scope A1, ZEISS, Germany).

Routine Blood Test
------------------

Routine blood test was performed at the end of the experiment. All mice were fasted but allowed to water freely for 12 h prior to collecting the blood sample. The blood samples were collected from the murine orbit, followed by the centrifugation in heparinized tubes. Hematologic indexes included white blood cell (WBC) count, red blood cell (RBC) count and platelet (PLT) count.

Statistical Analysis
--------------------

All the data were expressed as mean ± SD. One-way analysis of variance followed by Dunnett's test when appropriate. *P* \< 0.05 was considered to be statistically significant. The statistical analysis was performed using SPSS 18.0 software (SPSS, Chicago, IL, United States).

Results
=======

YGPs Inhibit DMM-Induced OA-Like Phenotype
------------------------------------------

To evaluate cartilage degradation induced by DMM surgery, Alcian Blue Hematoxylin/Orange G and Toluidine Blue stainings were subsequently performed. As shown in **Figure [1A](#F1){ref-type="fig"}**, no pathological findings of OA were observed in mice from sham group. In contrary, DMM-induced mice exhibited localized damage of articular cartilage, early osteophyte formation and increases in subchondral bone mass. By treated with YGPs, cartilage surface erosion and joints degradation were noticeably decreased. Histomorphometric analysis showed a significant reduction in tibial cartilage area and thickness in OA model mice (both, *P* \< 0.001). Likewise, prominent increase of tibial cartilage area (**Figure [1B](#F1){ref-type="fig"}**) and thickness (**Figure [1C](#F1){ref-type="fig"}**) also occurred after YGPs treatment compared with model group (*P* = 0.003; *P* = 0.002). Moreover, we analyzed the data using the histologic scoring system recommended by OARSI ([@B11]), and we found that DMM-induced mice had significantly higher scores compared to sham group (*P* \< 0.001), with significantly downregulated OARSI scores after treatment with YGPs (*P* = 0.005) (**Figure [1D](#F1){ref-type="fig"}**).

![Yougui pills (YGPs) protect against cartilage loss in DMM-induced mice. **(A)** Histological knee joint sections (50×) stained using Alcian Blue Hematoxylin/Orange G and Toluidine Blue. Joint degenerations are labeled (black arrows: cartilage degradation, blue arrows: osteophyte formation, yellow arrows: subchondral sclerosis). Cartilage architecture was evaluated using the Osteomeasure System to detemine the tibial cartilage area **(B)** and tibial cartilage thickness **(C)** OARSI scoring of the sections analyzed by histomorphometry was also performed **(D)** Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g001){#F1}

To assess the microarchitecture of the bone, the three-dimensional image was carried out using micro-CT. As shown in **Figure [2A](#F2){ref-type="fig"}**, YGPs prominently reduced DMM-induced osteophyte formation. The parameters including BV/TV, Tb. Th and Tb. Sp of each group are shown in **Figures [2B--D](#F2){ref-type="fig"}**. The results showed that, following the DMM surgery, all the parameters for the model group were significantly different compared to sham group (*P* \< 0.001). After YGPs treatment, the BV/TV and Tb. Th measurements of YGPs group were significantly lower than those of DMM-induced mice (*P* = 0.005, *P* \< 0.001). Conversely, the Tb. Sp measurements of the YGPs group were significantly higher than those of DMM-induced mice (*P* = 0.027). These results suggest that YGPs have a positive effect on bone health in DMM-induced mice.

![Changes in bone structure in DMM-induced mice. **(A)** Representative micro-CT images. Quantification of the **(B)** BV/TV, **(C)** Tb. Th and **(D)** Tb. Sp by static histomorphometry. Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g002){#F2}

DMM-Induced Downregulation of pSMAD-2 Is Enhanced by YGPs
---------------------------------------------------------

An important link in cartilage damage is the unbalance of synthesis and degradation of the ECM, an event marked by the expression of catabolic enymes such as MMP-13, and the key molecular of TGF-β/Smad signaling, pSMAD-2. Accordingly, it is possible that the chondroprotective effect on YGPs exhibited in **Figure [1](#F1){ref-type="fig"}** is associated with TGF-β/Smad signaling. To address this question, immunohistochemistry was conducted to evaluate COL-2, MMP-13 and pSMAD-2 protein expressional levels in the articular cartilage. As expected, DMM-induced mice had reduced levels of both COL-2 and pSMAD-2, and elevated levels of MMP-13 in cartilage compared to sham mice, indicating the suppression of TGF-β/Smad signaling (all, *P* \< 0.001) (**Figures [3A--C](#F3){ref-type="fig"}**). Mice treated with YGPs were protected from the DMM induced COL-2 and MMP-13 positive staining in cartilage (*P* = 0.006, *P* = 0.003), suggesting that the maintenance of cartilage architecture in YGPs group could be due to inhibition of matrix degradation (**Figures [3A,B](#F3){ref-type="fig"}**). Interestingly, pSMAD-2 positive cells were increased in YGPs group (*P* = 0.028) (**Figure [3C](#F3){ref-type="fig"}**), indicating that YGPs may have been from cartilage degradation in part due to reduced MMP-13 production by chondrocytes residing in cartilage via activation of TGF-β/Smad signaling.

![Yougui pills reduce MMP-13 and elevate pSMAD-2 expressional levels in articular cartilage of mice following DMM. Representative sagittal sections image (200 × ) **(A)** COL-2, **(B)** MMP-13 and **(C)** pSMAD-2 stained chondrocytes (brown; black arrows) with cell nuclei counterstained with hematoxylin (blue). Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g003){#F3}

YGPs Could Not Decelerate OA Progression in *TGF-βRII^Col2ER^* Mice
-------------------------------------------------------------------

The marked preservation of ECM produced by chondrocytes post-DMM in YGPs treated mice begged for subsequent investigation of the impact of YGPs on OA progression in *TGF-βRII^Col2ER^* mice. Firstly, we performed Alcian Blue Hematoxylin/Orange G and Toluidine Blue staining respectively to further explore the role of TGF-β/Smad signaling in the chondroprotective action of YGPs. Comparison of the sections from all groups revealed a severity of articular cartilage damage, subchondral sclerosis and osteophyte formation in *TGF-βRII^Col2ER^* mice. It should be noted that there were no discernable effects of YGPs treatment on inhibition of OA progression in *TGF-βRII^Col2ER^* mice (**Figure [4A](#F4){ref-type="fig"}**). Additional analyses were also performed using the histomorphometry approach as well as standardized OARSI cartilage scoring. Consistent with the histopathologic analysis, reduction of tibial cartilage area and thickness in *TGF-βRII^Col2ER^* mice were not mitigated significantly by YGPs treatment (*P* = 0.199, *P* = 0.328) (**Figures [4B,C](#F4){ref-type="fig"}**). Finally, the impact of YGPs on the articular cartilage in *TGF-βRII^Col2ER^* mice was also no significant difference based on OARSI scoring (*P* = 0.514) (**Figure [4D](#F4){ref-type="fig"}**). As analysis performed above, it should be noted that there were no significant differences in *TGF-βRII^Col2ER^* mice with or without YGPs treatment including tibial cartilage area and thickness, and OARSI cartilage scoring.

![Yougui pills could not inhibit cartilage degradation in TGF-βRII^Col2ER^ mice. **(A)** Histological knee joint sections (50×) stained using Alcian Blue Hematoxylin/Orange G and Toluidine Blue. Joint degenerations are labeled (black arrows: cartilage degradation, blue arrows: osteophyte formation, yellow arrows: subchondral sclerosis). Cartilage architecture was evaluated using the Osteomeasure System to detemine the tibial cartilage area **(B)** and tibial cartilage thickness **(C)** OARSI scoring of the sections analyzed by histomorphometry was also performed **(D)** Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g004){#F4}

Moreover, our micro-CT results also showed that YGPs almost can not inhibit the osteophyte formation (**Figure [5A](#F5){ref-type="fig"}**). In addition, BV/TV and Tb. Th were increased, and Tb. Sp was decreased in *TGF-βRII^Col2ER^* mice, whereas no significant improvement was observed in the animals treated with YGPs (**Figures [5B--D](#F5){ref-type="fig"}**).

![Changes in bone structure in TGF-βRII^Col2ER^ mice. **(A)** Representative micro-CT images. Quantification of the **(B)** BV/TV, **(C)** Tb. Th and **(D)** Tb. Sp by static histomorphometry. Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g005){#F5}

Upregulation of MMP-13 in *TGF-βRII^Col2ER^* Mice Is Not Ameliorated by YGPs
----------------------------------------------------------------------------

To understand better the role of TGF-β signaling in the chondroprotective action of YGPs, we further performed immunohistochemistry to evaluate COL-2 and MMP-13 protein expressional levels based on *TGF-βRII* gene deletion in chondrocyte. As shown in **Figure [6A](#F6){ref-type="fig"}**, *TGF-βRII^Col2ER^* mice had reduced levels of pSMAD-2 more than 80% in the cartilage compared to *TGF-βRII^fx/fx^* mice, suggesting that TGF-β/Smad signaling was almost blocked in our study. Interestingly, *TGF-βRII^Col2ER^* mice treated with YGPs were not protected from the COL-2 positive staining in the cartilage (*P* = 0.207) (**Figure [6B](#F6){ref-type="fig"}**). Accordingly, MMP-13 positive cells were not reduced in *TGF-βRII^Col2ER^* mice treated with YGPs (*P* = 0.226) (**Figure [6C](#F6){ref-type="fig"}**), indicating that YGPs almost had no effect on inhibition of matrix degradation with suppressing of TGF-β/Smad signaling. To summaries, no differences were observed in the articular cartilage, as chondrocytes were all actively producing similar levels of both COL-2 and MMP-13 in *TGF-βRII^Col2ER^* mice with or without YGPs treatment (**Figures [6B,C](#F6){ref-type="fig"}**).

![Upregulation of MMP-13 in TGF-βRII^Col2ER^ mice is not ameliorated by YGPs. Representative sagittal sections image (200×) **(A)** pSMAD-2, **(B)** COL-2 and **(C)** MMP-13 stained chondrocytes (brown; black arrows) with cell nuclei counterstained with hematoxylin (blue). Bars represent Mean ± SD (*n* = 10). ^∗^*P* \< 0.001.](fphar-08-00611-g006){#F6}

Routine Blood Test
------------------

To evaluate the effect of YGPs orally administered on hematologic values, routine blood test was performed at the end of the experiment, including WBC count, RBC count and platelet (PLT) count. As shown in **Figures [7A--C](#F7){ref-type="fig"}**, there were no significant differences in both healthy and YGPs treated mice. YGPs treatment did not cause a significant change in any of the hematologic parameters compared to the control groups.

![Hematological values in DMM-induced and TGF-βRII^Col2ER^ mice treated with YGPs. Hematological analysis was performed, including **(A)** White blood cell (WBC) count, **(B)** Red blood cell (RBC) count and **(C)** Platelet (PLT) count. Bars represent Mean ± SD (*n* = 10).](fphar-08-00611-g007){#F7}

Discussion
==========

In present study, experiments were performed to investigate the impact of YGPs on the joint degenerative process in a mouse model of DMM. Relative examination of cartilage architecture, area and thickness change revealed prominently chondroprotective effects in degenerative knee joints of OA. These new findings support the hypothesis that orally administration of YGPs is articular cartilage protective and disease modifying in osteoarthritic knee joints. Although the precise mechanisms have yet to be defined, significant increases in TGF-β signaling appear to be involved.

A number of previous researches have described TCM as being effective in inhibition articular cartilage degeneration in animal models of OA disease. For example, Zhu et al. described protective activity for cartilage via reducing expressions of MMP-3, ADAMTS-4 and elevating TIMP-1, TIMP-3 with the TCM Sanmiao formulae which was administered to rat model induced by potassium oxonate and cold bath ([@B37]). [@B36] reported similar benefits with Juanbi capsules in rabbits subjected to plaster cast fixation. *In vitro* models, Monotropein exhibited anti-apoptotic and anti-catabolic effects on rat OA chondrocytes treated by IL-β ([@B30]). Thus, our findings are in keeping with these previous studies and extend the benefits of TCM to include the more commonly employed, DMM-induced model of OA. According to TCM theory, TCM formulae may regulate diseases on the basis of its rich medicinal materials. The constituents of YGPs were separated and defined by HPLC analysis, and 10 components were determined as major active material basis. Additionally, no obvious abnormality on the hematologic parameters appeared in our study, including WBC, RBC and PLT (**Figures [7A--C](#F7){ref-type="fig"}**). This suggests that the extended use of YGPs for the prevention of OA dose not affect primary routine blood indexes.

Reproducing features of OA in animal is pivotal to have a better understanding of disease mechanism and to evaluate response to potential therapies. DMM surgical model is a frequently used chronic model of OA in mouse, and strongly associated with clinical process ([@B10]; [@B17]). The transaction of the medial menisco-tibial ligament alters the mechanical stability of the joint and accelerates cartilage erosion. DMM model has become a gold standard in the field ([@B8]). DMM surgery was applied to demonstrate the importance of the crucial aggrecan- and collagen-degenerating enzymes in articular cartilage damage in mice deficient in *Admats-5* ([@B9]; [@B28]) and *Mmp-13* ([@B22]). As expected in our study, DMM-induced mice exhibited significant reduced protein level of COL-2 as well as elevated level of MMP-13 (**Figures [2A,B](#F2){ref-type="fig"}**), indicating that the model of OA with the destruction of articular cartilage dynamic balance by enhancing the catabolic activity of ECM proteins was established successfully.

An experimental protocol was performed in the present study that involved oral administration of YGPs to mice that were induced to develop OA through DMM surgery. The dose of YGPs (3.5 g/kg/day) was chosen in the present study, which was set to be the body weight equivalent to the human dose according to the drug instruction ([@B34]). Structural evaluation of the articular cartilage of sham and osteoarthritic knee joints using both histomorphometric and OARSI scoring methods revealed that mice administered YGPs were chondroprotected (**Figures [1B--D](#F1){ref-type="fig"}**). Tibial articular cartilage was preserved (**Figure [1A](#F1){ref-type="fig"}**), possibly via reduction of MMP-13 and elevated pSMAD-2, the key molecule of TGF-β/Smad signaling (**Figures [2B,C](#F2){ref-type="fig"}**).

The role of TGF-β signaling in the pathogenesis of OA has gained attention in recent years. In chondrocytes, TGF-β signaling is through specific membrane receptors (type I receptors also known as activin receptor like kinases, ALKs and type II receptors, TGF-βRII) and its intracellular effectors, the Smad proteins ([@B29]). Inhibition of TGF-β/Smad signaling leads to increased damage to cartilage ([@B35]) and prevents osteophyte formation ([@B25]). To further explore whether the chondroprotection of YGPs in osteoarthritic mice is through TGF-β signaling, *Tgfbr2* was conditionally knocked out in the articular cartilage of mice at the age of 2 weeks in this study ([@B26]). As expected in the present study, severe articular cartilage damage was also observed in *TGF-βRII^Col2ER^* mice. While no overt chondroprotective effect was observed in articular cartilage of the *TGF-βRII^Col2ER^* mice supplemented with YGPs (**Figure [3A](#F3){ref-type="fig"}**). In addition, the lack of TGF-β/Smad signaling may activate runt-related transcription factor-2 (RUNX-2)-induced expression of MMP-13 ([@B2]). However, there were no discernable MMP-13 level changes of the supplements in *TGF-βRII^Col2ER^* mice (**Figure [4B](#F4){ref-type="fig"}**), suggesting a chondroprotective effect of YGPs may partially through TGF-β/Smad signaling in articular cartilage.

Overall, our data showed that YGPs are chondroprotective in OA through enhancing TGF-β/Smad signaling activity in articular cartilage, setting the stage for further mechanistic study and evaluation of joint structural modifications.
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